Dr Ashvind Prabahran

Learn more about Monash Health’s Haematology team.

Dr Ashvind Prabahran

Ashvind Prabahran is a Haematologist and BMT Physician with a special interest in myeloid disorders, bone marrow failure syndromes and allogeneic stem cell transplant. After completing clinical and laboratory training in Haematology, he was awarded the Maddie Riewoldt’s Vision/Victorian Cancer Agency Travelling Fellowship. Through this fellowship he completed a PhD through the ACRF laboratory at the Royal Melbourne Hospital and National Heart Lung and Blood Institute at the NIH in the United States. As part of this PhD he has published articles in the area of engraftment syndromes following allogeneic stem cell transplant and immune mediated bone marrow failure.

Top 5 publications

Prabahran A, Koldej R, Chee L, Szer J, Ritchie D. Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review. Bone Marrow Transplant. 2022 Oct;57(10):1489-1499. doi: 10.1038/s41409-022-01761-z. Epub 2022 Jul 23. PMID: 35871087.

Prabahran A.A, Koldej R, Chee L, Ritchie, D. Clinical features, pathophysiology and therapy of Poor Graft Function Post Allogeneic Stem Cell Transplantation. 2021, Blood Advances, doi: 10.1182/bloodadvances.2021004537

Prabahran A.A, Koldej R, Chee L, Wong E, Ritchie D. Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. 2021, Leukemia & Lymphoma, doi: 10.1080/10428194.2021.1872072

Koldej RM, Prabahran A, Tan CW, Ludford-Menting M, Morgan H, Holzwart N, Davis MJ, Ritchie DS. Spatial proteomics identifies a spectrum of immune dysregulation in acquired bone marrow failure syndromes. Frontiers in Immunology. 2023 Sep 25:1425;14:1213560. doi: 10.3389/fimmu.2023.1213560. eCollection 2023

Prabahran A.A, Tacey M, Fleming S, Wei A, Tate C, Marlton P, Wight J, Grigg A, Tuckfield A, Szer J, Ritchie D, Chee L. Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine. 2018, European Journal of Haematology, doi: 10.1111/ejh.13089